URGCP

Chr 7

upregulator of cell proliferation

Also known as: URG4

NCBI Gene: 55665ENSG00000106608UniProt: Q8TCY9

URG4 is upregulated in the presence of hepatitis B virus (HBV)-encoded X antigen (HBxAg) and may contribute to the development of hepatocellular carcinoma by promoting hepatocellular growth and survival (Tufan et al., 2002 [PubMed 12082552]).[supplied by OMIM, Mar 2008]

124
ClinVar variants
23
Pathogenic / LP
0.58
pLI score
0
Active trials
Clinical Summary— URGCP
⚡
Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.58) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
23 Pathogenic / Likely Pathogenic· 84 VUS of 124 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.40LOEUF
pLI 0.578
Z-score 4.22
OE 0.21 (0.12–0.40)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.32Z-score
OE missense 0.72 (0.66–0.78)
390 obs / 541.7 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.21 (0.12–0.40)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.72 (0.66–0.78)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.92
0≤1.21.6
LoF obs/exp: 7 / 33.3Missense obs/exp: 390 / 541.7Syn Z: 0.95

ClinVar Variant Classifications

124 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic22
Likely Pathogenic1
VUS84
Likely Benign9
Benign8
22
Pathogenic
1
Likely Pathogenic
84
VUS
9
Likely Benign
8
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
22
0
22
Likely Pathogenic
0
0
1
0
1
VUS
0
81
3
0
84
Likely Benign
0
6
1
2
9
Benign
0
1
0
7
8
Total088279124

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

URGCP · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway.
Cai J et al.·Oncotarget
2015
Downregulation of miR-16 via URGCP pathway contributes to glioma growth.
Hong L et al.·Sci Rep
2017
[Up-regulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma].
Xie C et al.·Zhonghua Yi Xue Za Zhi
2013
Regulation of URG4/URGCP and PPARα gene expressions after retinoic acid treatment in neuroblastoma cells.
Avci CB et al.·Tumour Biol
2013
URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M et al.·Oncotarget
2015
URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.
Xing S et al.·BMC Cancer
2015
Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a.
Xie C et al.·PLoS One
2012
Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
Hesham D et al.·J Neurooncol
2024
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools